Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

835

Employees835

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

835

Employees835

SRPT Key Statistics

Market cap

1.92B

Market cap1.92B

Price-Earnings ratio

-18.88

Price-Earnings ratio-18.88

Dividend yield

—

Dividend yield—

Average volume

5.16M

Average volume5.16M

High today

$18.41

High today$18.41

Low today

$17.45

Low today$17.45

Open price

$18.23

Open price$18.23

Volume

3.43M

Volume3.43M

52 Week high

$25.32

52 Week high$25.32

52 Week low

$10.42

52 Week low$10.42

Stock Snapshot

The current Sarepta Therapeutics(SRPT) stock price is $18.29, with a market capitalization of 1.92B. The stock trades at a price-to-earnings (P/E) ratio of -18.88.

As of 2026-07-01, Sarepta Therapeutics(SRPT) stock has fluctuated between $17.45 and $18.41. The current price stands at $18.29, placing the stock +4.8% above today's low and -0.7% off the high.

The Sarepta Therapeutics(SRPT)'s current trading volume is 3.43M, compared to an average daily volume of 5.16M.

In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $25.32 and a 52-week low of $10.42.

SRPT News

TipRanks 17h

H.C. Wainwright says Sarepta news does not signal full approvals

H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target after the FDA accepted the supplemental new drug appli...

Simply Wall St 1d

Sarepta Therapeutics Following FDA Filings And The Case For A Reset Valuation - simplywall.st

...

Benzinga 1d

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

• Sarepta Therapeutics shares are climbing with conviction. What’s fueling SRPT momentum? The FDA approved VYONDYS 53 in 2019 and AMONDYS 45 in 2021. The agen...

Analyst ratings

48%

of 29 ratings

Buy

27.6%

Hold

48.3%

Sell

24.1%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.